Imagion Biosystems (ASX:IBX) Common Stock : A$62.54 Mil (As of Dec. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Imagion Biosystems Common Stock?

Imagion Biosystems's quarterly common stock increased from Dec. 2023 (A$59.31 Mil) to Jun. 2024 (A$59.61 Mil) and increased from Jun. 2024 (A$59.61 Mil) to Dec. 2024 (A$62.54 Mil).

Imagion Biosystems's annual common stock increased from Dec. 2022 (A$56.83 Mil) to Dec. 2023 (A$59.31 Mil) and increased from Dec. 2023 (A$59.31 Mil) to Dec. 2024 (A$62.54 Mil).

Imagion Biosystems Common Stock Historical Data

The historical data trend for Imagion Biosystems's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Imagion Biosystems Common Stock Chart

Imagion Biosystems Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Common Stock

Get a 7-Day Free Trial

51.32

56.83

59.31

62.54

Imagion Biosystems Semi-Annual Data
	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Common Stock	Get a 7-Day Free Trial											56.83	57.60	59.31	59.61	62.54

Imagion Biosystems Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Imagion Biosystems Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Imagion Biosystems Ltd (ASX:IBX) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

IBXXF:USA

Address

5601 Oberlin Drive, Suite 100, San Diego, CA, USA, 92121

Website

https://www.imagionbiosystems.com

Imagion Biosystems Ltd operates in the field of non-invasive detection of specific solid tumor cancers by use of magnetic nanoparticles. Its principal continuing activities consisted of Nanotechnology; Biotechnology; Cancer Diagnostics; and Medical Imaging using Magnetic Resonance and Superparamagnetic Relaxometry. The company only operating segment - Research and Development. Its principal business activities consist of nanotechnology, biotechnology, cancer diagnostics, and medical imaging using Superparamagnetic Relaxometry. In addition, the company is engaged in the research and development of its clinical phase lead product which is intended for the detection and staging of metastatic HER2 breast cancer.

Imagion Biosystems Headlines

No Headlines